Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

Takahashi, Harumi, Wilkinson, Grant R., Nutescu, Edith A., Morita, Takashi, Ritchie, Marylyn D., Scordo, Maria G., Pengo, Vittorio, Barban, Martina, Padrini, Roberto, Ieiri, Ichiro, Otsubo, Kenji, Kashima, Toshitaka, Kimura, Sosuke, Kijima, Shinichi, Echizen, Hirotoshi·2006·Pharmacogenetics and Genomics
DOI 10.1097/01.fpc.0000184955.08453.a8

Cited by (374)

Items 301–374 of 374

  1. Real-World Safety and Effectiveness of a 4-Factor Prothrombin Complex Concentrate in Japanese Patients Experiencing Major Bleeding: A Post-marketing Surveillance Study
    Masahiro Yasaka, Michiyasu Suzuki, Shigeki Kushimoto, Ayako Kiyonaga, Antoinette Mangione, Yuki Niwa, Naoki Terasaka · 2024 · Cardiology and Therapy
  2. Predisposing Factors for Adverse Drug Reactions
    Jimmy José, Francisco José de Abajo · 2024 · Springer eBooks
  3. Quantitative methods to improve bivalirudin dosing in pediatric cardiac ICU patients
    Lindsey M. Brinkley, Zasha Francheska Vazquez-Colon, Aashay Patel, Matthew S. Purlee, Terrie Vasilopoulos, Mark Steven Bleiweis, Jeffrey Phillip Jacobs, Giles John Peek, Helen A. Moore · 2025 · Perfusion
  4. Pharmacogenetics in Clinical and Forensic Toxicology: Opioid Overdoses and Deaths
    Saeed A. Jortani, M. Elaine Stauble, Steven H. Wong · 2011 · Humana Press eBooks
  5. Warfarin resistance in Japanese population
    Takehiko Nagao · 2010 · Nosotchu
  6. Effect of oral anticoagulation therapy on duration of hospital stay and medical costs in patients with cardiogenic embolism stroke who were discharged to home
    Ichiro Deguchi, Masaki Takao, Takeshi Hayashi, Takuya Fukuoka, Toshiyuki Ikezawa, Norio Tanahashi · 2015 · Nosotchu
  7. Population frequencies of vkorc1 c1173t polymorphism, which determining the organism sensitivity to warfarin, in forest nenets and nganasans of northern siberia
    R. P. Tiis, Ludmila P. Osipova, Elena Nikolaevna Voronina, М. Л. Филипенко · 2020 · Nauchno-prakticheskii zhurnal «Medicinskaia genetika»
  8. Prediction of the Impact of CYP2C9 and VKORC1 Genotypes on Warfarin–Sorafenib Interactions in Whites and Asians
    Kazuhiko Asari, Harumi Takahashi · 2020 · Pharmacogenomics
  9. Effects of CYP2C9 and VKORC1 polymorphisms and drug interactions on coumarin anticoagulation control
    Tom Schalekamp · 2007 · Utrecht University Repository (Utrecht University)
  10. Pharmacology of Vitamin K Antagonists
    Jaekyu Shin, Steven R. Kayser · 2011
  11. Personalised treatment with oral anticoagulant drugs : clinical and economic issues
    Talitha I. Verhoef · 2013 · Utrecht University Repository (Utrecht University)
  12. A quest for individualized warfarin therapy
    Hirotoshi Echizen · 2006 · Japanese Journal of Thrombosis and Hemostasis
  13. Warfarin dosing by genotype did not improve time in therapeutic range
    Andrew S Dunn · 2014 · Annals of Internal Medicine
  14. Management of Anticoagulation Before and After Gastrointestinal Endoscopy
    Sun‐Young Lee, Thomas J. Savides · 2010 · The American Journal of Gastroenterology
  15. Studies on warfarin treatment with emphasis on inter-individual variations and drug monitoring
    Abdimajid Osman · 2007 · DiVA (Linkoping University)
  16. Major determinants of outcome and dosing in warfarin treatment
    Jonatan D. Lindh · 2009 · Figshare
  17. Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants
    J.A. Perini, Daniela D. Vargens, I.S.C. Santana, E.H. Moriguchi, Ândrea Ribeiro‐dos‐Santos, M. Tsutsumi, Guilherme Suarez‐Kurtz · 2009 · Brazilian Journal of Medical and Biological Research
  18. Farmacogenética da varfarina : proposta de um algoritmo para a predição de dose
    Mariana Rodrigues Botton · 2010 · Americanae (AECID Library)
  19. Cardiovascular Disease Pharmacogenomics
    Bishwanath Chatterjee · 2013 · Springer eBooks
  20. Pharmacogenomics Aspect of Warfarin Therapy
    Matthew D. Krasowski · 2012
  21. Current Status of Pharmacogenetics in Antithrombotic Drug Therapy
    Eva Gak, Rivka Inzelberg · 2012 · InTech eBooks
  22. Study Of Genetic And Pharmacokinetic Issues Related To Efficacy And Toxicity Of Warfarin In Pakistani Subjec
    Aisha, Qayyum · 2014 · HEC National Digital Library
  23. The application of a perceptron model to classify an individual's response to a proposed loading dose regimen of Warfarin
    Cen Wan, Irina V. Biktasheva, Lane, Steven · 2012 · arXiv (Cornell University)
  24. Genetic polymorphisms associated with the responses and adverse effects of drugs
    Keiko Maekawa, Yoshiro Saito, Kimie Sai, Jun‐ichi Sawada · 2009 · Japanese Journal of Thrombosis and Hemostasis
  25. In AF or VTE, acenocoumarol or phenprocoumon dosing by genotype did not affect time in therapeutic range
    Andrew S Dunn · 2014 · Annals of Internal Medicine
  26. In AF or VTE, warfarin dosing by genotype improved time in therapeutic range but not clinical outcomes
    Andrew S Dunn · 2014 · Annals of Internal Medicine
  27. Pharmacogenomics: a perspective of personalized medicine in CHD treatment as a model
    Aidas Pranculis, Zita Aušrelė Kučinskienė, Vaidutis Kučinskas · 2011 · Acta medica Lituanica
  28. Pharmacogenetics of warfarin: clinical implications
    Harumi Takahashi · 2010 · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics
  29. Development of a Warfarin-Dosing Algorithm in Asian Patients: A Pharmacogenomic Approach
    Christina L. Aquilante · 2007 · Personalized Medicine
  30. Percutaneous closure of the left atrial appendage in atrial fibrillation: an alternative if standard treatment fails?
    Pieter De Meester, Vincent Thijs, Rik Willems, Werner Budts · 2009 · Interventional Cardiology
  31. Structure of VKOR and anticoagulant mechanism of warfarin
    Takashi Morita · 2010 · Japanese Journal of Thrombosis and Hemostasis
  32. Identification of a Synonymous Polymorphism Within the Cytochrome P4502C9 Gene That Interferes With Identification of the CYP2C9*2 Allele
    Edward P. Womack, Kristen K. Reynolds, Roland Valdes, Mark W. Linder · 2007 · Therapeutic Drug Monitoring
  33. CYP2C19 polymorphisms in drug metabolism and response
    Ming Chang · 2014 · Figshare
  34. Pharmacogenetics of oral anticoagulant therapy.
    Teodora Pop, D. N. Chirilă, Anca Dana Buzoianu · 2013
  35. GENETIC VARIABILITY AND INTERETHNIC DIFFERENCES OF SELECTED PHARMACOGENETICALLY RELEVANT GENES IN AVERAGE HUNGARIAN AND
    Roma Population Samples · 2010
  36. Allele Frequency and Genotype Distribution of 9 SNPs in the Kazakh
    PopulationN Iskakova, Aliya A. Romanova, Elena Nikolaevna Voronina, Nurgul S. Sikhayeva, Liliya Alexandrovna Belozerceva, М. Л. Филипенко, M Erlan, General Genetics Llp, Aisha N. Iskakova · 2014
  37. Modelling in oral anticoagulation treatment
    Peter Brønnum Nielsen · 2010 · VBN Forskningsportal (Aalborg Universitet)
  38. Ambulatory Warfarin Management
    Surasak Saokaew · 2015 · Springer eBooks
  39. Moderate Effect of GGCX Polymorphisms on Patients Warfarin Dosage Requirement- A Meta-Analysis
    Zhiying Luo · 2015 · American Journal of Life Sciences
  40. Pharmaceutical Study on Anticoagulation in Case of Coadministration of Bucolome and Warfarin Potassium
    Atsuhide Hamada, Kyoko Ogi, Hisashi Mimoto, Mitsuhiko Miyamura, Shojiro Kyotani, Yutaka Nishioka · 2008 · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
  41. Translational PK/PD study of the anticoagulant warfarin
    Harumi Takahashi · 2010 · Folia Pharmacologica Japonica
  42. Warfarin Response and Vitamin K Epoxide Reductase Complex 1 in African Americans and
    Caucasians Schelleman, Z Chen, Carmel Kealey, AS Whitehead, Jason D. Christie, Maureen Price, Colleen M Brensinger · 2007
  43. Development of a single-tube PCR-pyrosequencing method for simultaneous and rapid detection of the genetic polymorphism of warfarin metabolizing enzymes
    Hong Shi, Runliu Yu, Jinfei Ma, Xuyi Ren · 2011 · Hereditas (Beijing)
  44. Pharmacogenetics and anticoagulant therapy: two cases of genetically determined response to warfarin.
    Nuno Cortez‐Dias, Maria José Correia, Ana Coutinho, Catarina Fernandes, A. Nunes Diogo, Mário G. Lopes · 2009 · PubMed
  45. ビタミンKエポキシド還元酵素の遺伝子多型 : ワルファリン感受性および血管疾患との関連( 「ビタミンと遺伝子多型」-ビタミンK-)
    友乃 内田 · 2013 · ビタミン
  46. FARMACOGENÉTICA DO ANTICOAGULANTE ORAL WARFARINA E O IMPACTO DE POLIMORFISMOS NOS GENES CYP2C9 E VKORC1
    Jamila Alessandra Perini · 2009
  47. Pharmacogenetic Impact of VKORC1 and CYP2C9 Allelic Variants on Warfarin Dose Requirements in a
    Lina Marcela Hoyos Palacio, Diana Falla, Ignacio Tobon, Fernando Mejía, John Eugene Lewis, Ariel F. Martinez, Mauricio Arcos‐Burgos, Maurício Camargo · 2010
  48. Correlations Between the Enantio- and Regio-selective Metabolisms of Warfarin
    Harumi Takahashi, Minami Ohara, Soichi Shibata, Ming Ta Michael Lee, Larisa H. Cavallari, Edith A. Nutescu, Maria Gabriella Scordo, Vittorio Pengo, Roberto Padrini, Koichiro Atsuda et al. · 2016 · Pharmacogenomics
  49. Pharmacogenomics in Therapeutics
    Sandeep Kaushal · 2009
  50. Pharmacogenetics and Pharmacogenomics
    M. Perera, Federico Innocenti · 2009 · Elsevier eBooks
  51. Change in Prothrombin Time International Normalized Ratio due to Drug Interaction between Celecoxib and Warfarin
    Shinya Suzuki, Takashi Kawaguchi, Kenzo Ikari, Junichi Kusano, Eiki Ando · 2017 · Iyakuhin Johogaku
  52. Present and Future Status of Pediatric Mechanical Circulatory Support
    Hajime Ichikawa · 2017 · Japanese Society of Pediatric Cardiology and Cardiac Surgery
  53. Genetic-based dosing in orthopaedic patients beginning warfarin therapy Running Title: Genetic-Based Warfarin Dose Refinement
    Eric A. Millican, Petra A. Lenzini, Paul E. Milligan, Leonard Grosso, Charles Eby, Elena Deych, Gloria R. Grice, John C. F. Clohisy, Robert L. Barrack, Deepak Voora et al. · 2017
  54. Essays on supply chain and healthcare analytics
    Yijun Wang · 2017
  55. Personalised Medicine in New Zealand: A new approach to healthcare delivery
    Patrick A. Gladding · 2011 · ResearchSpace (University of Auckland)
  56. WITHDRAWN: Genetic polymorphisms of pharmacogenomic VIP variants in the Wa population from southwest China
    Chan Zhang, Weiwei Guo, Yujing Cheng, Wanlu Chen, Xin Yang, Run Dai, Mengdan Yan, Qi Li · 2018 · Drug Metabolism and Pharmacokinetics · Retracted
  57. The prevalence of allelic variants of VKORC1, CYP2C9 and CYP4F2 genes in Zaporizhzhia region population
    M. Yu. Kolesnik, Yа. М. Mykhailovskyi · 2019 · Current issues in pharmacy and medicine science and practice
  58. Pharmacogenetics of therapeutics
    Abdel B Halim · 2019 · Elsevier eBooks
  59. Management of antithrombotic agents and current issues in patients undergoing endoscopic submucosal dissection
    Chan Hyuk Park · 2019 · International Journal of Gastrointestinal Intervention
  60. Avaliação de polimorfismo da enzima citocromo P450 em pacientes com síndrome antifosfolípide e seu impacto no controle da anticoagulação
    Carlos Ewerton Maia Rodrigues, Jozélio Freire de Carvalho, Roberto Paulo Correia de Araujo · 2020 · Revista de Ciências Médicas e Biológicas
  61. Vitamin K-Zyklus, VKORC1 und die molekularen Mechanismen der oralen Antikoagulation
    Matthias Watzka, Johannes Oldenburg · 2010 · Springer eBooks
  62. Pharmacogenomics
    Hitoshi Zembutsu · 2019 · Springer eBooks
  63. Pharmacogenomics
    Simon de Denus, Michaels Phillips, Jean‐Claude Tardif · 2009 · Springer eBooks
  64. Pharmacogenetics in clinical practice: Challenges and opportunities
    Gordana Dragović, Nada Dolić, Božana Dimitrijević, Milan Jovanović, Marko Barović, Djordje Jevtović · 2015 · Medicinska istrazivanja
  65. A Case of Significant Fluctuation of Prothrombin Time-international Normalized Ratio with Change, and Cancellation of the Transluminal Nutrient Preparation under Warfarin Administration
    Naruhito Matsumoto, Yukiko Miyoshi, Tatsuro Yamamoto, Miki Shimada · 2021 · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
  66. The 5 most frequently asked questions about factor Xa inhibitors
    Tzu‐Fei Wang, Marc Carrier · 2022 · Hematology
  67. Two worlds, one goal : A Clinician’s Perspective on Laboratory Analyses in Anticoagulant Treatment
    Kerstin Arbring · 2023 · Linköping University medical dissertations
  68. DETERMINATION OF THE DYNAMICS OF NATRIURETIC PEPTIDE IN RESPONSE TO VOLUME LOAD IN PATIENTS WITH ACUTE SURGICAL PATHOLOGY OF THE ABDOMINAL CAVITY
    K. Yu. Krenov, А. І. СУХОДОЛЯ · 2024 · Bulletin of Problems Biology and Medicine
  69. Pharmacogenetics and pharmacokinetics of warfarin
    J Šlechtová, Zdeňka Hajšmanová · 2009 · Klinická biochemie a metabolismus
  70. Genomic Analysis for Preventing Complications due to Proton Pump Inhibitor and Warfarin Combination Therapy after Open-Heart Surgery
    Haruka Kimura, Mitsumasa Hata, Motomi Shiono, Hisakuni Sekino · 2014 · Japanese Journal of Cardiovascular Surgery
  71. Étude pharmacogénomique sur l’utilisation de la warfarine en pratique clinique réelle
    Mélina Marin-Leblanc · 2010
  72. Apports des modèles non linéaires à effets mixtes dans l'étude de la variabilité pharmacocinétique et pharmacodynamique des médicaments antithrombotiques
    Xavier Delavenne · 2011
  73. Advances in research and clinical decision strategies for anticoagulation timing in acute ischemic stroke patients with atrial fibrillation
    Qi Wang, Jing Huang, Jingwen Xia, Linjie Xie, Chaochen Yin, Ruijuan Gang, Yujie Tang, Pengyuan Wang, Yuetong Luo, Xiong Yu et al. · 2026 · Journal of the Neurological Sciences
  74. SYNTHESIS AND BIOCHEMICAL STUDIES ON SULFATED MONOMERS OF LOW MOLECULAR WEIGHT LIGNINS
    Jenson Verghese · 2009 · VCU Scholars Compass (Virginia Commonwealth University)